WGCNA of the sample characteristics and proteins of the two oat varieties under drought stress. by Caijin Chen (3107787)

Subjects:

Changes in the growth of two oat varieties under drought stress and normal water supply treatments. by Caijin Chen (3107787)

Subjects:

Child mortality rate per 1,000 person-years during the 18-month follow-up period. by Samuel Sendagala (21417164)

Subjects:

Volcano map of DAPs. by Caijin Chen (3107787)

Subjects:

KEGG pathway enrichment bubble map of the top 20 DAPs. by Caijin Chen (3107787)

Subjects:

Normalized sample plots for each treatment for data quality control. by Caijin Chen (3107787)

Subjects:

Basic physical and chemical properties of the soils. by Caijin Chen (3107787)

Subjects:

Kaplan–Meier cumulative survival curve for infants exposed and not exposed to HIV. by Samuel Sendagala (21417164)

Subjects:

Mortality dataset used in analysis. by Samuel Sendagala (21417164)

Subjects:

Different responses of two oat varieties to drought stress. by Caijin Chen (3107787)

Subjects:

GO enrichment of DAPs, including BP, CC, and MF. by Caijin Chen (3107787)

Subjects:

Optimization of Linear Loading Strategy for Fuel Cell Initiation Based on Gaussian Process Regression Model (Supporting Information) by Jianbin SU (19730371)

Data Sheet 1_Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greate... by Ayman Alhejazi (21092054)

“…Background<p>Multiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. …”

AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner. by Matthew Drill (22258391)

“…Cell numbers were significantly decreased in cells after treatment with AZ10606120 (50µM) compared to both temozolomide (TMZ; 50µM) treatment and untreated controls. …”

Study selection criteria. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

PRISMA flow chart. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

Changes in relative abundance of genera in both therapeutic groups. by Flavia Furlaneto (20161022)

Mean muscle activation patterns across the gait cycle during walking with mediolateral (ML) forces for <i>A)</i> able-bodied individuals and <i>B)</i> individuals after stroke duri... by Sanne Ettema (18786312)

Mean muscle activation patterns across the gait cycle during walking with anteroposterior (AP) forces for <i>A)</i> able-bodied individuals and <i>B)</i> individuals after stroke d... by Sanne Ettema (18786312)